Originally dba as KL50 Therapeutics LLC, the firm was renamed Aztek in November 2021, then (a few months later) was announced as doing business as Aztek Bio Inc - jst soon after (in April 2022) was adjusted to Aztek Bio LLC. Yale School of Medicine scientists -- to include Azrec co-founders - revealed in the magazine Science compounds that target drug-resistant gliomas. Most glioma tumors lack the methyl transferase MGMT and initially respond to the DNA methylation agent temozolomide. Frequently, the cells acquire resistance through loss of the mismatch repair (MMR) pathway. Authorsof the article indicated having created agents that cause a dynamic DNA lesion via a two-step chemical process. The first lesion can be reversed by MGMT in healthy cells, but transforms into a more toxic secondary lesion in MGMT-deficient tumor cells, resulting in MMR-independent cell death.
